Who was Barbara Mitchell?
  1. Author Library
  2. Author Library

Author Library

Ottawa’s pharmacare plan would likely reduce drug coverage for millions of Canadians
By Kristina M.L. Acri, née Lybecker | March 15, 2024
National pharmacare program—the threat to patients and innovation
By Kristina M.L. Acri, née Lybecker | November 4, 2023
Pandemic showed that Canada needs a thriving biopharmaceutical industry
By Kristina M.L. Acri, née Lybecker | August 17, 2022
An Evaluation of the Proposed PMPRB Amendments
By Kristina M.L. Acri, née Lybecker | August 16, 2022
Proposed ‘drug price’ changes threaten access for Canadian patients
By Kristina M.L. Acri, née Lybecker | July 29, 2021
Trudeau government move undermines COVID-19 response
By Kristina M.L. Acri, née Lybecker | August 6, 2020
Biologics and Biosimilars: A Primer
By Kristina M.L. Acri, née Lybecker | July 9, 2020
Trade deal will hurt—not help—COVID vaccine mission
By Kristina M.L. Acri, née Lybecker | April 15, 2020
USMCA will stunt potentially lifesaving innovation
By Kristina M.L. Acri, née Lybecker | January 14, 2020
Pharmacare plan will likely limit drug access and hurt patients
By Kristina M.L. Acri, née Lybecker | October 1, 2019
Canada can learn from Swiss and Dutch drug coverage
By Bacchus Barua, Kristina M.L. Acri, née Lybecker | September 6, 2019
Universal Insurance for Pharmaceuticals in Switzerland and the Netherlands
By Kristina M.L. Acri, née Lybecker, Bacchus Barua | July 11, 2019
Colorado wants your drugs
By Kristina M.L. Acri, née Lybecker | June 13, 2019
National pharmacare can hurt patients more than it helps
By Kristina M.L. Acri, née Lybecker | March 18, 2019
The Unintended Consequences of National Pharmacare Programs: The Experiences of Australia, New Zealand, and the UK
By Kristina M.L. Acri, née Lybecker | December 13, 2018
Ottawa's planned changes to review process will limit patient access to lifesaving drugs
By Kristina M.L. Acri, née Lybecker | September 17, 2018
New pricing regulations may restrict access to innovative drugs in Canada
By Bacchus Barua, Kristina M.L. Acri, née Lybecker | August 2, 2018
Implications of the proposed changes to Canada's pharmaceutical pricing regulations
By Kristina M.L. Acri, née Lybecker | July 20, 2018
Counterfeit drug trade poses increasing danger to Canadian patients
By Kristina M.L. Acri, née Lybecker | March 2, 2018
Pharmaceutical Counterfeiting: Endangering Public Health, Society, and the Economy
By Kristina M.L. Acri, née Lybecker | February 8, 2018
Canada’s inadequate intellectual property rights protections hurt patients and the economy
By Kristina M.L. Acri, née Lybecker | January 30, 2017
Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up
By Kristina M.L. Acri, née Lybecker | January 24, 2017
Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals
By Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson | October 14, 2016
Strengthening Canada’s intellectual property protections for biologic medicine may save lives
By Kristina M.L. Acri, née Lybecker | July 12, 2016
The Biologics Revolution in the Production of Drugs
By Kristina M.L. Acri, née Lybecker | July 12, 2016
The Benefits of Incremental Innovation
By Steven Globerman, Kristina M.L. Acri, née Lybecker | June 19, 2014
Bulk prescription drug purchasing: It's not all savings
By Nadeem Esmail, Kristina M.L. Acri, née Lybecker | August 6, 2013
Trade and Economic Benefits of Enhanced Intellectual Property Protection for Pharmaceuticals in Canada
By Nadeem Esmail, Kristina M.L. Acri, née Lybecker, Laura Dawson | July 9, 2013
Bulk Purchase of Pharmaceuticals: The Experiences of the United States, Europe, and New Zealand
By Kristina M.L. Acri, née Lybecker | May 9, 2013